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Abstract
Introduction Cancer-testis antigens (CTAGs) are expressed
solely in germ cells and in malignant tissues. They are targets of
immune responses mediated by cytotoxic T cells in some
cancers, and there is much interest in developing vaccines that
induce these responses. The purpose of the present study was
to ascertain the frequency of expression of CTAGs in breast
cancer.
Methods Breast tumours were collected sequentially in the
Southampton Tumour Bank from donors who had given written
informed consent. Stored samples where there was sufficient
material were sampled in sequence. An initial series of 42
tumours was screened for expression of 17 different CTAGs. A
second panel of 40 tumours was screened for the expression of
those antigens present in the first panel.
Results Ninety-three per cent of tumours in the first series
expressed at least one CTAG, and 62% expressed the single
antigen CTAG1. Eighty per cent of tumours in the second series
expressed at least one CTAG, 50% expressing CTAG1.
Tumours exhibiting higher risk features tended to express more
CTAGs.
Conclusion More than two-thirds of breast cancers would be
covered by a vaccine directed against just three CTAGs –
CTAG1, BAGE1, and MAGEA10 – all of which are known to be
targets of cytotoxic-T-lymphocyte responses.
Introduction
The immune system has been demonstrated capable of
mounting a number of different types of response against
malignancy, either spontaneously or following immunisation. In
some cases, the development of such responses has been
associated with tumour regression.
Of particular interest are tumour antigens recognised through
the class 1 antigen presentation system. Class-1-restricted
(usually CD8-positive) cytotoxic T lymphocytes (CTL) recog-
nise MHC class 1 molecules to which are bound short pep-
tides derived from the intracellular breakdown of endogenous
proteins. The antigen-specific T-cell receptor recognises the
cell surface complex of peptide contained within the antigen-
binding cleft of the class 1 molecule. Antigen recognition
results in CTL killing of the antigen-bearing cell.
Understanding the process of assembly of the class 1 mole-
cule-peptide antigen complex is crucial when considering
strategies for tumour antigen discovery, and for assessing the
presence of known tumour antigens in human cancers. The
primary source of antigens for the MHC class I processing
pathway is defective ribosomal products (that is, polypeptides
that are only partially translated and are not folded; see, for
example, Yewdell and colleagues [1]). These defective ribos-
omal products are rapidly degraded in the proteasome and
transferred to the endoplasmic reticulum for assembly with
class 1 molecules. Because defective ribosomal products are
the antigen source, peptide antigens may be derived not just
from those fully assembled proteins that are demonstrably
present in the cell, but also from short fragments arising from
translation of normally untranslated regions, introns or alter-
nate reading frames; there are examples of effective recogni-
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tion by CTL of cells in each of these cases. Assessment of
what antigens might be available for presentation by the class
1 system in a cell is therefore best performed by analysis of
RNA transcripts rather than by protein expression analyses.
A variety of human tumour antigens have now been identified.
These antigens fall into several categories, of which the cate-
gory cancer-testis antigens (CTAGs) has received particular
attention [2]. These antigens are expressed in germ cells and
in malignancies, but not at other sites. More than 15 families of
genes encoding CTAGs have now been identified, and char-
acterisation of these families has included demonstration that
they are not expressed in normal somatic tissues.
Estimates of the frequency of expression of a particular CTAG
in a particular tumour type have usually been made when such
antigens were first described. Fewer systematic attempts to
identify what proportion of any particular tumour type will
express any CTAGs have been published. It is necessary,
however, to establish whether or not such antigens are com-
monly found in a given tumour type to determine whether it is
worth pursuing attempts at a vaccination strategy in that
tumour.
Patterns of expression of some CTAGs have been reported in
breast cancer by several authors [3-6]. In the current study we
examined a larger panel of CTAGs in a series of 42 breast can-
cers, and then sought to confirm the pattern of distribution in
a second series of 40 breast cancers collected at a later date.
We report that several known CTL antigens are expressed fre-
quently in breast cancer.
Materials and methods
Breast cancer cDNA
Frozen specimens of breast tumours were obtained from the
Southampton Tumour Bank. All specimens had been obtained
from individuals undergoing surgery for primary invasive breast
cancer. Samples were identified and removed by a pathologist
and were frozen as soon as possible. All specimens were
taken from donors who had given prior written consent to their
tumours being taken and stored in this way. Local research
ethics committee approval has been given to the creation of
the tumour bank, and local research ethics committee
approval was obtained for this study.
Tumour samples were taken from the tumour bank in the order
in which they had been stored – with the qualification that if
only one aliquot of tumour was available, that sample was not
used for this study.
Frozen tumour specimens w e r e  m a d e  i n t o  5  μm sections
using a cryostat (Bright Instrument Company, Huntingdon,
UK) and the sections transferred to RNALater (Ambion
(Europe) Ltd, Huntingdon, UK). These sections were then
stored at -20°C until use. poly-A RNA was subsequently puri-
fied using oligo-dT magnetic beads (Dynal Biotech UK, Wirral,
UK) according to the manufacturers' protocol. The RNA
amount was standardised using ribogreen quantitation (Invit-
rogen Ltd, Paisley, UK).
First-strand cDNA was synthesised using M-MLV-H-Point
mutant RT (Promega UK Ltd, Southampton, UK). The DNA
quality was confirmed by an actin PCR. In every case, an equal
amount of RNA was used in an equivalent reaction tube with
all the other reagents added except for RT (RT-negative sam-
ple). RT-positive and RT-negative specimens were routinely
used in all reactions to provide an adequate negative control.
Primers
Primer sequences were selected using published sequence
data and the Primer3 software [7].
For the MAGEA family, where possible, primers were
designed to give coverage of more than one family member.
Coverage of MAGEA1, MAGEA2, MAGEA3, MAGEA4,
MAGEA5, MAGEA10, MAGEA11 and MAGEA12 was
achieved. The results for these primers are presented in
Tables 1 and 2 as positivity or negativity for the relevant group
of antigens (data not shown for the uniformly negative findings
with MAGEA1, MAGEA4 and MAGEA11).
Primers were designed to be intron spanning. Some of the
primer pairs give a positive band with genomic DNA. In all such
cases the band from genomic DNA was of a different size to
that obtained from cDNA, and a genomic control was routinely
included in all PCR experiments.
The specificity of each primer set was confirmed and the reac-
tion conditions were defined by PCR with 50 pg plasmid DNA
containing an IMAGE clone known to contain the relevant
sequence [8]. Cycle numbers (between 30 and 40) were set
to permit easy identification of a band on an agarose gel.
IMAGE clones
Bacterial stocks transformed with plasmids containing the rel-
evant image clones were obtained from MRC Geneservices
(now known as Geneservice Ltd, Cambridge, UK). Bacteria
were cultured and the plasmid DNA extracted.
Polymerase chain reaction
The PCR was performed preferentially with Titanium Taq DNA
polymerase (BD Biosciences, Oxford, UK). Accuprime DNA
Polymerase (Invitrogen Ltd, Paisley, UK) was used when it was
not possible to design primers fulfilling the stringent require-
ments of Titanium Taq. Preliminary experiments with a range of
commercially available Taq DNA polymerases had shown that
these two polymerases had the highest sensitivity and specif-
icity when used with cDNA derived from frozen breast tumour
specimens.Available online http://breast-cancer-research.com/content/9/4/R46
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Table 1
Expression of cancer-testis antigens by breast tumours in the first series
Sample CTp11 SCP1 BAGE1 CTAG1 CTAG2 MAGEA10 MAGEA23
12newa
MAGEA5 Number of 
cancer-
testis 
antigens 
expressed
Number of 
positive 
samples
61 5 62 5 0135
1 --------0
2 --------0
3 + --+ --+ + 4
4 -+ + -----2
5 ---+ ----1
6 --------0
7 ---+ ----1
8 -+ ------1
9- - ++- +++5
1 0 ---+ ----1
1 1 ---+ ----1
1 2 -+ -+ ----2
1 3 ---+ ----1
1 4 + --+ ----2
1 5 -+ ------1
1 6 ---+ ----1
1 7 -+ ----+ + 3
1 8 ---+ ----1
1 9 -+ + + ----3
2 0 +++- - - - - 3
2 1 -+ ------1
2 2 -+ ------1
2 3 +- ++- - - - 3
2 4 ---+ ----1
2 5 --------0
2 6 ---+ ----1
2 7 -+ -+ ----2
2 8 -+ ------1
2 9 --------0
3 0 --------0
3 1 ---+ ----1
3 2 + + -+ ----3
3 3 -+ ------1
3 4 -+ -+ ----2
3 5 ---+ ---+ 2
3 6 + --+ ----2
3 7 -+ + -----2
3 8 ---+ ----1
3 9 ---+ ----1
4 0 ---+ ----1
4 1 -------+ 1
4 2 ---+ ----1
-, negative result; +, positive result. aThe Primer pair MAGEA2312new recognises cDNA encoding MAGEA2, MAGEA3, and MAGEA12.Breast Cancer Research    Vol 9 No 4    Taylor et al.
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Table 2
Expression of cancer-testis antigens by breast tumours in the second series
Sample CTp11 SCP1 BAGE1 CTAG1 CTAG2 MageA10 MageA231
2newa
MAGEA5 Number of 
cancer-
testis 
antigens 
expressed
Number of 
positive 
samples
1 8 842 0 5612
4 3 -+ -+ ----2
4 4 ++- ++- - +5
4 5 -----+ --1
4 6 -+ + + ----3
4 7 -----+ --1
4 8 ---+ ----1
4 9 --------0
5 0 ---+ ----1
5 1 --------0
5 2 -----+ --1
5 3 --------0
5 4 +- - - +- - - 2
5 5 + --+ ----2
5 6 ---+ ----1
5 7 ---+ ----1
5 8 + -------1
5 9 --------0
6 0 --------0
6 1 --------0
6 2 + --+ ----2
6 3 -+ -+ ----2
6 4 + -------1
6 5 --------0
6 6 ---+ ----1
6 7 + ----+ --2
6 8 +- +- - - - - 2
6 9 ---+ ----1
7 0 + ----+ --2
7 1 + + -+ ----3
7 2 + --+ ----2
7 3 + --+ ----2
7 4 + --+ ----2
7 5 + + ------2
7 6 ---+ + -+ -3
7 7 +- +- - - - - 2
7 8 --------0
7 9 +++- - - - - 3
8 0 -+ -+ ----2
8 1 +- - ++- - - 3
8 2 +- - +++ +5
-, negative result; +, positive result. aThe Primer pair MAGEA2312new recognises cDNA encoding MAGEA2, MAGEA3, and MAGEA12.Available online http://breast-cancer-research.com/content/9/4/R46
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Depending on the primer pair combination, between 30 and
40 cycles of PCR were performed on RT-positive and RT-neg-
ative cDNA samples, together with a positive control of a plas-
mid containing the relevant cDNA. Water and genomic DNA
were routinely included as negative controls. The use of a
genomic DNA control removed the risk of false positives due
to the existence of as yet unknown pseudogenes.
The results were scored as follows. Where the positive control
yielded a product of the appropriate size, and all samples (both
RT-positive and RT-negative) gave a negative result, the reac-
tion was scored as negative for all breast cancer specimens
and was not repeated. Where positive results were obtained
in the RT-positive specimens but not in the RT-negative spec-
imens, and the negative controls were negative, the reaction
was repeated once, or in some cases twice. Where two reac-
tions were performed, only those samples that gave a positive
result in both reactions and where the negative controls were
consistently negative were counted as positive samples.
Where three reactions were performed, those specimens for
which two out of three reactions gave a positive result but all
the negative controls were negative were counted as positive
samples.
Adjuvant! Online
Patient and tumour characteristics were entered into the Adju-
vant! Online version 7 programme [9] to obtain estimates of
risk of breast cancer recurrence and of breast-cancer-specific
mortality over 10 years [10].
Results
Of 16 CTAGs examined in the first panel of 42 breast cancer
samples, seven antigens were found not to be expressed in
any of the specimens: SSX2, SSX4, CTAG2, CAGE1,
MAGEA1, MAGEA4 and MAGEA11. The results for the other
antigens are presented in Table 1.
Thirty-nine out of 42 (93%) tumours expressed at least one of
the antigens examined, and 24/42 (57%) expressed two or
more antigens. The most commonly expressed antigen was
CTAG1, found in 62% of tumours. Sixty-seven per cent of
tumours expressed at least one of CTAG1 or BAGE1, and
83% expressed at least one of CTAG1, BAGE1 or SCP1 (the
same percentage of tumours was found to express at least one
of CTAG1, CTp11 or SCP1).
Having identified a group of antigens and antigen combina-
tions of potential interest in breast cancer, we then examined
whether the findings were reproducible.
A second panel of 40 breast tumours was examined for the
antigens expressed in the first series, and the pattern of
expression was found to be very similar (Table 2), although not
identical. Eighty per cent of tumours expressed at least one of
the antigens, and 53% expressed two or more antigens.
CTAG1 was again the most commonly expressed antigen
(50%). Sixty per cent of specimens expressed at least one of
CTAG1 or BAGE1, rising to 70% if MAGEA10 was also con-
sidered. Inclusion of SCP1 added nothing to the CTAG1/
BAGE combination. Seventy-three per cent of samples
expressed at least one of CTAG1 or CTp11 (SCP1 did not
increase this proportion, although inclusion of MAGEA10
raised the expression to 80%).
Five of the specimens examined were from tumours found to
contain only ductal carcinoma in situ. Three of these samples
expressed one antigen (one each of CTAG1, CTp11 and
SCP1), one sample expressed both CTp11 and BAGE1, and
one sample expressed no CTAGs (although on review this
specimen contained very little tumour).
Known risk factors (oestrogen receptor status, tumour grade,
nodal status and clinical stage) were examined to determine
whether there was any correlation with the pattern of expres-
sion of CTAGs in the invasive cancers studied. There was a
trend towards expression of more CTAGs with more aggres-
Figure 1
(a) Number of CTAGs expressed by tumor grade (a) Number of CTAGs expressed by tumor grade. (b) Calculated risk of 
recurrence by number of CTAGs expressed. CTAGs, cancer-testis 
antigens.Breast Cancer Research    Vol 9 No 4    Taylor et al.
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sive features (for example, Figure 1a), but this did not achieve
statistical significance.
The 10-year risk of recurrence or death from breast cancer
was calculated for each patient using the Adjuvant! Online
program. There was an apparent trend towards increased
expression of CTAGs with increased risk, but this was not sta-
tistically significant (Figure 1b).
Discussion
There is much interest in the potential for the use of vaccina-
tion against CTAGs in the treatment of solid human tumours.
A limited number of reports have been published previously
looking at breast cancer, but we have examined a larger panel
of antigens than previously reported.
CTAG1 has been reported to be expressed in 10–42% of
breast cancers in previous studies, with the highest frequency
found in the largest study – 88 Japanese breast cancer
tumours reported by Sugita and colleagues [11]. What the
present report adds is that, in two separate series of tumours
in the Southampton Tumour Bank, collected at different times,
more than 80% of tumours were found to express at least one
antigen.
Given that no individual antigen is expressed in all breast can-
cers, we were interested in examining the frequency of various
combinations. In the first series of 42 tumours, 83% were
found to express at least one of CTAG1, CTp11 or SCP1.
Seventy-three per cent of tumours in the second series
expressed at least one of these three antigens. There would be
undoubted attraction in a polyvalent vaccine with coverage of
a larger proportion of tumours than is possible with vaccines
directed against a single antigen. Polyvalent vaccines contain-
ing multiple melanoma CTL antigens are already in clinical
development.
T-cell responses, primarily CD8-mediated CTL responses, are
believed to be the most important component of immune
responses directed against CTAGs in human cancers. The ini-
tial descriptions of CTAGs were based on identification of
antigens recognised by CTLs [12]. An alternative strategy,
SEREX, has been used subsequently to identify potential
CTAGs; thus far, no CTL responses have been reported
against some CTAGs identified in this way. The antigens
CTp11 and SCP1 both fall into this group of CTAGs for which
no CTL responses have yet been reported. We therefore
examined patterns of expression of CTAGs known to induce
CTL in humans.
CTL responses have been identified against CTAG1, BAGE1
and MAGEA10 [13-15]. A vaccine directed against these
three antigens would cover more than two-thirds of the
tumours in each series of breast cancer examined in the
present study. Construction of such a vaccine is entirely pos-
sible with currently available technology.
We did not analyse the HLA status of the individuals from
whom the tumour specimens were derived, but have no reason
to believe this would be different from that of the UK popula-
tion at large. CTAG1 is the most studied of the three antigens
with identified responses, and peptides have been identified
as being presented by HLA A2, HLA A31, HLA B7, HLA B35,
HLA B51, HLA Cw3 and HLA Cw6. The frequency of these
HLA alleles in the general population ranges between 5% and
44% [16]. MAGEA10 peptides are known to be presented by
HLA A2 (44%) and HLA B53 (2%). BAGE1 has been studied
least, and there is only the initial report of its presentation by
HLA Cw16 (7%). There is every reason to believe that other
restriction elements (HLA alleles that present antigenic pep-
tides) will be identified as further studies are undertaken. Anal-
ysis of the BAGE1 protein sequence using syfpeithi MHC
epitope prediction software [17] identifies potential high-affin-
ity peptide epitopes for HLA A2, HLA A3, HLA A11, HLA A24,
HLA A26, HLA B8, HLA B18, HLA B44 and HLA B51. Simi-
larly, an even larger number of potential high-affinity epitope
and restriction element pairs exists for MAGEA10.
Clinical trials of immunisation against several CTAGs are
underway. A search of the http://ClinicalTrials.gov website
[18] identifies 14 current trials involving immunisation against
CTAG1 or against MAGE. Although a number of trials of
immunisation strategies in breast cancer are currently recruit-
ing, we are not aware of any involving CTAGs. Our work, and
that of others, would support inclusion of breast cancer
patients in screening for entry into trials of vaccines against
CTAGs.
An interesting question for the future will be, if vaccination can
induce demonstrable CTL responses against CTAGs
expressed in breast cancer, whom should be offered such vac-
cination? Early trials looking to establish clinical benefit are
likely to be performed in individuals with advanced disease,
perhaps when few other treatment options remain. Breast can-
cer, almost uniquely, is a condition where active management
of metastatic disease can include long periods of treatment
with nonimmunosuppressive therapies (hormonal agents, her-
ceptin). There is therefore also an opportunity for quite pro-
longed vaccination schedules without the concern that the
concomitant use of cytotoxic therapy will disrupt the evolution
of a normal immune response. The setting of minimal residual
disease following surgery and adjuvant therapies, however,
may be where vaccination could have its greatest impact, per-
haps increasing the number of long-term cures.
We examined whether there is an association between
expression of CTAGs and markers of tumour aggressiveness.
There was a trend towards higher numbers of CTAGs
expressed with various features known to be associated withAvailable online http://breast-cancer-research.com/content/9/4/R46
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poorer prognosis. Similar findings were reported by Sugita
and colleagues for CTAG1 [11], although in our dataset we
could find no association for CTAG1 alone.
We entered the tumour features into the AdjuvantOnline pro-
gramme, a web-based prognostication tool that offers predic-
tions of likelihood of breast cancer recurrence and death over
a 10-year period. There was a trend towards expression of
greater numbers of CTAGs with both increased risk of recur-
rence and breast-cancer-specific mortality.
Park and colleagues [6] examined 12 breast cancers as part
of a larger series also including lung and head and neck can-
cers. They found expression of at least one antigen of
MAGEA1–MAGEA6 in 11/12 (91%) of samples. It is not clear
whether this represents a population difference (all their sam-
ples were derived from Korean patients), represents an
increased sensitivity of the nested PCR technique they used,
or represents chance. The same group subsequently demon-
strated that they could detect PCR evidence of circulating
tumour cells in a proportion of patients with breast cancer
[19]. Identification of circulating tumour cells may lead to ear-
lier diagnosis of breast cancer, or to its recurrence. On the
basis of the data presented here, the use of primers for
CTAG1, MAGEA10 and BAGE1 might increase the sensitivity
of such a test.
Conclusion
The present article has shown that a large proportion of breast
cancers express CTAGs. A vaccine directed against just three
antigens known to be capable of eliciting CTL responses
(CTAG1, MAGEA10 and BAGE1) would be of potential utility
in up to 70% of breast cancers.
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